Bluebird Bio, now rebranded as Genetix Biotherapeutics, focuses on delivering transformative genetic therapies for patients with rare genetic diseases, including sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy
Bluebird Bio, now rebranded as Genetix Biotherapeutics, focuses on delivering transformative genetic therapies for patients with rare genetic diseases, including sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Their therapies are designed to treat the underlying causes of these diseases through gene therapy.